oral semaglutide microdose GLP-1: & Tirzepatide Microdose GLP-1 Protocol

Because these pathways dont intersect, researchers studying one mechanism generally cannot draw direct conclusions about the other, even though both are frequently discussed under the umbrella of fat-loss peptides. Research Use-Case Differences AOD-9604s research use case remains narrow and largely unresolved, given that its principal 24-week clinical trial found no statistically significant difference from placebo

No fasting requirement

Gonalves R.V., et al

Its also important to consider the fact that patients with prior cardiovascular disease or who are at a heightened risk for a cardiovascular event also respond to GLP-1 therapies, as these therapies have cardiovascular benefits

My concern is that prescribers are doing these online sessions without extensive assessment or knowing the patient and their broader picture of complex obesity as well as their own GP might